BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heine SJ, Diaz-mcnair J, Martinez-becerra FJ, Choudhari SP, Clements JD, Picking WL, Pasetti MF. Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD. Vaccine 2013;31:2919-29. [DOI: 10.1016/j.vaccine.2013.04.045] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Vander Broek CW, Chalmers KJ, Stevens MP, Stevens JM. Quantitative proteomic analysis of Burkholderia pseudomallei Bsa type III secretion system effectors using hypersecreting mutants. Mol Cell Proteomics 2015;14:905-16. [PMID: 25635268 DOI: 10.1074/mcp.M114.044875] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
2 Martinez-Becerra FJ, Chen X, Dickenson NE, Choudhari SP, Harrison K, Clements JD, Picking WD, Van De Verg LL, Walker RI, Picking WL. Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine. Infect Immun 2013;81:4470-7. [PMID: 24060976 DOI: 10.1128/IAI.00859-13] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
3 Farhani I, Nezafat N, Mahmoodi S. Designing a Novel Multi-epitope Peptide Vaccine Against Pathogenic Shigella spp. Based Immunoinformatics Approaches. Int J Pept Res Ther 2019;25:541-53. [DOI: 10.1007/s10989-018-9698-5] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
4 Jneid B, Rouaix A, Féraudet-Tarisse C, Simon S. SipD and IpaD induce a cross-protection against Shigella and Salmonella infections. PLoS Negl Trop Dis 2020;14:e0008326. [PMID: 32463817 DOI: 10.1371/journal.pntd.0008326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lee S, Picking WL, Tzipori S. The immune response of two microbial antigens delivered intradermally, sublingually, or the combination thereof. Microbes Infect 2014;16:796-803. [PMID: 25111827 DOI: 10.1016/j.micinf.2014.07.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
6 Sierocki R, Jneid B, Orsini Delgado ML, Plaisance M, Maillère B, Nozach H, Simon S. An antibody targeting type III secretion system induces broad protection against Salmonella and Shigella infections. PLoS Negl Trop Dis 2021;15:e0009231. [PMID: 33711056 DOI: 10.1371/journal.pntd.0009231] [Reference Citation Analysis]
7 Jneid B, Moreau K, Plaisance M, Rouaix A, Dano J, Simon S. Role of T3SS-1 SipD Protein in Protecting Mice against Non-typhoidal Salmonella Typhimurium. PLoS Negl Trop Dis 2016;10:e0005207. [PMID: 27992422 DOI: 10.1371/journal.pntd.0005207] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
8 Arabshahi S, Nayeri Fasaei B, Derakhshandeh A, Novinrooz A. In silico design of a novel chimeric shigella IpaB fused to C terminal of clostridium perfringens enterotoxin as a vaccine candidate. Bioengineered 2018;9:170-7. [PMID: 29091543 DOI: 10.1080/21655979.2017.1373535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Sagi S, Konduru B, Parida M. Heterologous expression of Intimin and IpaB fusion protein in Lactococcus lactis and its mucosal delivery elicit protection against pathogenicity of Escherichia coli O157 and Shigella flexneri in a murine model. Int Immunopharmacol 2020;85:106617. [PMID: 32464569 DOI: 10.1016/j.intimp.2020.106617] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kapoor N, Ndungo E, Pill L, Desalegn G, Berges A, Oaks EV, Fairman J, Pasetti MF. Efficient production of immunologically active Shigella invasion plasmid antigens IpaB and IpaH using a cell-free expression system. Appl Microbiol Biotechnol 2021. [PMID: 34932164 DOI: 10.1007/s00253-021-11701-4] [Reference Citation Analysis]
11 Chitradevi S, Kaur G, Sivaramakrishna U, Singh D, Bansal A. Development of recombinant vaccine candidate molecule against Shigella infection. Vaccine 2016;34:5376-83. [DOI: 10.1016/j.vaccine.2016.08.034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
12 Chitradevi ST, Kaur G, Uppalapati S, Yadav A, Singh D, Bansal A. Co-administration of rIpaB domain of Shigella with rGroEL of S. Typhi enhances the immune responses and protective efficacy against Shigella infection. Cell Mol Immunol 2015;12:757-67. [PMID: 25640657 DOI: 10.1038/cmi.2014.86] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
13 Muthuramalingam M, Whittier SK, Picking WL, Picking WD. The Shigella Type III Secretion System: An Overview from Top to Bottom. Microorganisms 2021;9:451. [PMID: 33671545 DOI: 10.3390/microorganisms9020451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Heine SJ, Franco-Mahecha OL, Chen X, Choudhari S, Blackwelder WC, van Roosmalen ML, Leenhouts K, Picking WL, Pasetti MF. Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice. Immunol Cell Biol 2015;93:641-52. [PMID: 25776843 DOI: 10.1038/icb.2015.24] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
15 Bulir DC, Liang S, Lee A, Chong S, Simms E, Stone C, Kaushic C, Ashkar A, Mahony JB. Immunization with chlamydial type III secretion antigens reduces vaginal shedding and prevents fallopian tube pathology following live C. muridarum challenge. Vaccine 2016;34:3979-85. [PMID: 27325352 DOI: 10.1016/j.vaccine.2016.06.046] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
16 Arabshahi S, Derakhshandeh A, Nayeri Fasaei B, Novinrooz A. In-silico design and production of a novel antigenic chimeric Shigella IpaB fused to C-terminal of Clostridium perfringens enterotoxin. Mol Biol Rep 2019;46:6105-15. [PMID: 31473892 DOI: 10.1007/s11033-019-05046-5] [Reference Citation Analysis]
17 Arizmendi O, Kumar P, Zheng Q, Stewart JP, Picking WD, Picking W, Martinez-Becerra FJ. Vaccination With Mouse Dendritic Cells Loaded With an IpaD-IpaB Fusion Provides Protection Against Shigellosis. Front Immunol 2019;10:192. [PMID: 30800131 DOI: 10.3389/fimmu.2019.00192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Felegary A, Nazarian S, Kordbacheh E, Fathi J, Minae ME. An approach to chimeric subunit immunogen provides efficient protection against toxicity, type III and type v secretion systems of Shigella. Int Immunopharmacol 2021;100:108132. [PMID: 34508943 DOI: 10.1016/j.intimp.2021.108132] [Reference Citation Analysis]
19 Charro N, Mota LJ. Approaches targeting the type III secretion system to treat or prevent bacterial infections. Expert Opinion on Drug Discovery 2015;10:373-87. [DOI: 10.1517/17460441.2015.1019860] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 5.9] [Reference Citation Analysis]
20 Marshall NC, Finlay BB. Targeting the type III secretion system to treat bacterial infections. Expert Opinion on Therapeutic Targets 2013;18:137-52. [DOI: 10.1517/14728222.2014.855199] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
21 Das S, Howlader DR, Zheng Q, Ratnakaram SSK, Whittier SK, Lu T, Keith JD, Picking WD, Birket SE, Picking WL. Development of a Broadly Protective, Self-Adjuvanting Subunit Vaccine to Prevent Infections by Pseudomonas aeruginosa. Front Immunol 2020;11:583008. [DOI: 10.3389/fimmu.2020.583008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
22 Sinha A, Dey A, Saletti G, Samanta P, Chakraborty PS, Bhattacharya MK, Ghosh S, Ramamurthy T, Kim JO, Yang JS, Kim DW, Czerkinsky C, Nandy RK. Circulating Gut-Homing (α4β7+) Plasmablast Responses against Shigella Surface Protein Antigens among Hospitalized Patients with Diarrhea. Clin Vaccine Immunol 2016;23:610-7. [PMID: 27193041 DOI: 10.1128/CVI.00205-16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
23 Heine SJ, Diaz-McNair J, Andar AU, Drachenberg CB, van de Verg L, Walker R, Picking WL, Pasetti MF. Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes. J Immunol 2014;192:1630-40. [PMID: 24453241 DOI: 10.4049/jimmunol.1302743] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
24 Ashkenazi S, Cohen D. An update on vaccines against Shigella. Ther Adv Vaccines 2013;1:113-23. [PMID: 24757519 DOI: 10.1177/2051013613500428] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
25 Davod J, Fatemeh DN, Honari H, Hosseini R. Constructing and transient expression of a gene cassette containing edible vaccine elements and shigellosis, anthrax and cholera recombinant antigens in tomato. Mol Biol Rep 2018;45:2237-46. [PMID: 30244396 DOI: 10.1007/s11033-018-4385-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
26 Turbyfill KR, Clarkson KA, Vortherms AR, Oaks EV, Kaminski RW. Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of Shigella Artificial Invaplex. mSphere 2018;3:e00583-17. [PMID: 29600284 DOI: 10.1128/mSphere.00583-17] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
27 Ndungo E, Andronescu LR, Buchwald AG, Lemme-Dumit JM, Mawindo P, Kapoor N, Fairman J, Laufer MK, Pasetti MF. Repertoire of Naturally Acquired Maternal Antibodies Transferred to Infants for Protection Against Shigellosis. Front Immunol 2021;12:725129. [PMID: 34721387 DOI: 10.3389/fimmu.2021.725129] [Reference Citation Analysis]
28 Vander Broek CW, Stevens JM. Type III Secretion in the Melioidosis Pathogen Burkholderia pseudomallei. Front Cell Infect Microbiol 2017;7:255. [PMID: 28664152 DOI: 10.3389/fcimb.2017.00255] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
29 Bulir DC, Waltho DA, Stone CB, Liang S, Chiang CK, Mwawasi KA, Nelson JC, Zhang SW, Mihalco SP, Scinocca ZC, Mahony JB. Chlamydia Outer Protein (Cop) B from Chlamydia pneumoniae possesses characteristic features of a type III secretion (T3S) translocator protein. BMC Microbiol 2015;15:163. [PMID: 26272448 DOI: 10.1186/s12866-015-0498-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
30 Heine SJ, Franco-Mahecha OL, Sears KT, Drachenberg CB, van Roosmalen ML, Leenhouts K, Picking WL, Pasetti MF. A Combined YopB and LcrV Subunit Vaccine Elicits Protective Immunity against Yersinia Infection in Adult and Infant Mice. J Immunol 2019;202:2005-16. [PMID: 30787109 DOI: 10.4049/jimmunol.1800985] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]